MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

Summary

This study will evaluate the safety and tolerability of MK6186 and the change from baseline in plasma HIV-1 RNA after seven consecutive days of dosing.

Timeline

Start

2010-10-10

Primary completion

2011-06-30

Completion

2011-06-30

Publications

• Results Schurmann D, Huser A, Pfafflin F, Cilissen C, De Lepeleire I, Larson PJ, Anderson MS, Rizk ML, Hofmann J, Daumer M, Stegemann MS, Stoch SA, Wagner F, Iwamoto M. A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-Infected Participants. AIDS Res Hum Retroviruses. 2025 Jan;41(1):11-19. doi: 10.1089/AID.2023.0152. Epub 2024 Oct 3.

Drugs

Indications